Senior Vice President for Cancer Prevention and Population Sciences
Chair, Department of Cancer Prevention and Population Sciences
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo New York USA 14263
Tel: 716 845-8444
Fax: 716 845-8487
E-mail: james.marshall@roswellpark.org

Dr. James R. Marshall joined the faculty of Roswell Park Cancer Institute (RPCI) in 2002 as Senior Vice President for Cancer Prevention and Population Sciences, and Chair of the Department of Cancer Prevention and Population Sciences. He came to RPCI from Arizona Cancer Center, Tucson, where since 1996, he served as Associate Director of Cancer Prevention and Control and Professor of Public Health and Medicine at the University of Arizona College of Medicine.

Dr. Marshall earned his doctoral degree in Sociology from the University of California at Los Angeles in 1977. He joined the faculty of the Department of Sociology at the University at Buffalo (UB) where he served until 1981. From 1981 to 1996, Dr. Marshall was a faculty member of the Department of Social and Preventive Medicine, School of Medicine & Biomedical Sciences rising in rank from Assistant to Full Professor (1981-1983), and the School of Health-Related-Professions (1991-1996), both at UB.

Dr. Marshall’s research interests focus on the identification and testing of chemoprevention strategies in human populations; evaluating diet as a means of preventing breast cancer recurrence; epidemiologic analysis of predictors of genetic mutation in adenomatous polyps; familial colon cancer registries; and independent associations between diet and breast and endometrial cancers.

Dr. Marshall is a member of a number of professional organizations, including the American Association for Cancer Education, the American Association for Cancer Research, the American Epidemiologic Society, the American Society for Nutritional Sciences, the American Society of Preventive Oncology and the Society for Epidemiologic Research. He recently served with the National Academy of Sciences investigating antioxidant supplementation of the American diet.

Dr. Marshall is Chair of the CALGB Cancer Control & Health Outcomes Prevention Subcommittee; Chair of Prevention, GU Committee, Southwest Oncology Group; and panel member of the NIH/NCI IRG Parent Committee for Cancer Center Support Grants. He is also a member of the International Advisory Panel: Cancer Prevention Legacy Initiative, of the Alberta Cancer Board of Canada.

Dr. Marshall has authored or co-authored more than 240 journal publications, book chapters and abstracts. He is an Associate Editor for Oncology; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research (CaPR).

Research Program

Three major components to this research:

1. Selenium as a chemopreventive agent: We are testing selenium as a chemopreventive agent against prostate, lung, and colon cancers. Against all of these cancers, we are focusing on high-risk populations.
2. Use of biomarkers to measure chemoprevention efficacy: We are especially interested in characteristics of neoplastic but not yet malignant lesions that might reflect progression toward or regression from malignancy.
3. Molecular epidemiology: Use of molecular characteristics of tumors as a possible key to their etiology, as well as consideration of genetic polymorphisms as they affect the association of environmental exposures and cancer risk.

Selected Peer-Reviewed Publications

• Dong Y, Lee SO, Zhang H, Marshall JR, Gao AC, Ip C. Prostatic specific antigen (PSA) expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Research (64):19-22, 2004.
• Chen Z, Staten LK, Maskarinec G, Arendell L, Bruhn R, Marshall JR. The relationship between mammographic density and body composition. International Journal of Body Composition Research 2(1): 23-29, 2004.
• Staten LK, Gregory-Mercado KY, Ranger-Moore J, Will JC, Giuliano AR, Ford ES, Marshall JR. Provider counseling, health education, and community health workers: The Arizona WISEWOMAN project. Journal of Women’s Health 13(5): 547-556, 2004.
• Marshall JR, Reid M, Duffield-Lillico AJ. Response Re: Selenium Supplementation and Secondary Prevention of Nonmelanoma Skin Cancer in a Randomized Trial (Journal of the National Cancer Institute 95(19):1477-1481, 2003). Journal of the National Cancer Institute 96 (4), 333-334, 2004.
• Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D3 and the risk of prostate cancer. Journal of Steroid Biochemistry & Molecular Biology, 90(1-5): 533-7, 2004.
• Reid ME, Stratton MS, Duffield-Lillico AJ, Fakih M, Natarajan N, Larry Clark, Marshall JR. A report of high-dose selenium supplementation: response and toxicities. Journal of Trace Elements in Medicine and Biology 18:69-74, 2004.
• Natarajan L, Rock CL, Major JM, Thomson CA, Caan BJ, Flatt SW, Chilton JA, Hollenbach KA, Newman VA, Faerber S, Ritenbaugh CK, Gold E, Stefanick ML, Jones LA, Marshall JR, Pierce JP. On the importance of using multiple methods of dietary assessment. Epidemiology 15(6): 738-745, 2004.
• Steck-Scott S, Forman MR, Sowell A, Borkowf CB, Albert PS, Slattery M, Brewer B, Caan B, Paskett E, Iber F, Kikendall W, Marshall JR, Shike M, Weissfeld J, Snyder K, Schatzkin A, Lanza E. Carotenoids, vitamin A and risk of adenomatous polyp recurrence in the polyp prevention trial. International Journal of Cancer 112(2): 295-305, 2004.
• Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, Iber F, Kikendall W, Marshall JR, Shike M, Weissfeld J, Brewer B, Schatzkin A, Lanza E, The Polyp Prevention Study Group. The association of calcium and vitamin D with risk of colorectal adenomas. The Journal of Nutrition 135(2): 252-258, 2005.
• Zhang H, Dong Y, Zhao H, Brooks JD, Hawthorn L, Nowak N, Marshall JR, Gao AC, Ip C. Microarray data mining for potential selenium targets in chemoprevention of prostate cancer. Cancer Genomics & Proteomics 2:97-114, 2005.
• Stranges S, Marshall JR, Trevisan M, Natarajan N, Donahue RP, Combs GF, Farinaro E, Clark LC, Reid ME. Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. American Journal of Epidemiology 163:694-699, 2006.
• Reid MR, Duffield-Lillico AJ, Sunga A, Fakih M, Alberts DS, Marshall JR. Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. International Journal of Cancer 118:1777-1781, 2006.
• Sabaichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basier JW, Lemer SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized controlled short-term trial of I-selenomethionine: a Southwest Oncology Group study. Clinical Cancer Research 12 (7): 2178-2184, 2006.
• Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 15 (8): 1479-84, 2006.
• Cai L, Mu LN, Lu H, Lu QY, You NC, Yu SZ, Le AD, Zhao J, Zhou XF, Marshall JR, Heber D, Zhang ZF. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 15(2): 294-300, 2006.
• Gregory-Mercado K, Staten LK, Gillespie C, Thomson CA, Ranger-Moore J, Giuliano A, Will J, Ford E, Marshall JR. Ethnicity and nutrient inadequacies among Arizona WISEWOMAN participants. J Women’s Health (Larchmt). May 2007.
• Lanza E, Binbing Y, Murphy G, Albert PS, Caan B, Marshall JR, Lance P, Paskett ED, Weissfeld J, Slattery M, Burt R, Iber F, Shike M, Kikendall JW, Brewer BK, Schatzkin A, The Polyp Prevention Trial Study Group. The Polyp Prevention Trial – continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and –vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 16(9):1745-1752, 2007.
• Ondracek RP, Parker F, Allen A, Davis W, Ray M, McCann W, Marshall JR. Standardization of nuclear norphometry-based biomarkers. Analytical and Quantitative Cytology and Histology 29(5):309-16, Oct 2007.
• Reid ME, Duffield-Lillico AJ, Slate E, Natarajan N, Turnbull B, Jacobs E, Combs GF Jr, Alberts DS, Clark LC, Marshall JR. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer 60(2):155-63, Mar-Apr 2008.
• Parsons JK, Newman V, Mohler J, Pierce JP, Flatt S, Marshal JR. Dietary modification in prostate cancer patients on active surveillance: a randomized, multi-center feasibility study. BJU Int 101(10):1227-31, May 2008.
• Parsons JK, Newman V, Mohler J, Pierce JP, Paskett E, Marshall, JR. The men’s eating and living (MEAL) study: A Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology, Epub Feb 2008.
• Liayemo AO, Murphy G, Sansbury L, Wang Z, Albert PS, Schatzkin A, Caan B, Marshall JR, Lance P, Paskett ED, Weissfeld J, Slattery ML, Burt R, Iber F, Shike M, Kikendall JW, Lanza E, The Polyp Prevention Trial Study Group. Risk factors for high-risk adenoma recurrence using the post-polypectomy colonoscopy surveillance guidelines. Ann Intern Med 148(6):416-26, Mar 2008.
• Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami H-O, Arlsan A, Beeson WL, van den Brandt PA, Buring JE, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Lacey Jr JV, Leitzmann M, Lukanova A, Marshall JR, Miller AB, Patel AV, Rodriguez C, Rohan TE, Ross JA, Wolk A, Zhang SM, Smith-Warner SA. Height, body mass index and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 17(4):902-12, Apr 2008.